Welcome to Seeking Alpha's Wall Street Breakfast, where we cover the top news for investors every morning.

It's good to have you here on this Monday, the 6th of April. I'm Julie Morgan. PepsiCo has withdrawn its backing from a major London music festival, following backlash over the decision to feature Kanye West as the headliner.

West, who now goes by Yeh, was recently announced as the headline Act for the Wireless Festival,

set to take place in July at Finsbury Park.

Organizers had promoted the event under the branding Pepsi Max Presents Wireless, but the beverage

giant confirmed it would no longer be involved. The artist is scheduled to perform across all three

days of the festival as part of a broader effort to reestablish his career after years of controversy.

The booking has also drawn political scrutiny in the UK. Prime Minister Kier Starrmer

described the decision as troubling in comments to a British tabloid, adding to pressure surrounding the

event. The UK is reportedly trying to charm Anthropic to expand its presence in the country. It comes as a fight continues

to brew between the AI startup and the U.S. Department of War. The Financial Times reported

that staff at the UK's Department for Science, Innovation, and Technology have written proposals

for Anthropic, which include an office expansion in London and a dual listing.

Anthropic and that UK department did not immediately respond to a request for comment from seeking Alpha.

Anthropic CEO is set to visit Britain in late May as part of a trip to meet European customers and policymakers.

Anthropic currently employs about 200 people

in the UK, 60 of them researchers, and last year appointed former Prime Minister Rishi Sunak as a senior

advisor. Last month, competitor OpenAI committed to expanding in London, making the city its biggest research hub outside the U.S.

The U.S. government and Anthropic have been an illegal tussle since the Trump administration

banned the use of the company's technology after designating it as a supply chain risk.

Anthropic PBC reportedly is also weighing an IPO as soon as October. Soleno Therapeutics is up 30% in pre-market action. This follows a Financial Times report that Neurokron Biosciences is in advance talks to buy the biotech firm in a $2.5 billion-plus deal.

The deal could value Soleno in the low to mid-50s per share or in excess of $2.5 billion.

...